Trial Outcomes & Findings for A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients (NCT NCT00690521)

NCT ID: NCT00690521

Last Updated: 2024-10-10

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

8 participants

Primary outcome timeframe

First Intervention (4 days), Washout (7 days), and Second Intervention (4 days)

Results posted on

2024-10-10

Participant Flow

8 patients enrolled and received drug treatment.

Participant milestones

Participant milestones
Measure
Arm 1-Furosemide + Hydrochlorothiazide Then Furosemide + Metolazone
A Randomized, double-blind, crossover study designed to compare the efficacy of furosemide in combination with hydrochlorothiazide or metolazone in congestive heart failure patients. First Intervention- Furosemide and Hydrochlorothiazide (4 days) Washout (7 days) Second Intervention-Furosemide + Metolazone (4 days) Combined results for both therapies are being reported since it cannot be determined which arm/group was assigned to Hydrochlorothiazide or metolazone
Arm-2 Furosemide + Metolazone Then Furosemide + Hydrochlorothiazide
A Randomized, double-blind, crossover study designed to compare the efficacy of furosemide in combination with hydrochlorothiazide or metolazone in congestive heart failure patients. First Intervention-Furosemide + Metolazone (4 days) Washout (7 days) Second Intervention-Furosemide and Hydrochlorothiazide (4 days) Combined results for both therapies are being reported since it cannot be determined which arm/group was assigned to Hydrochlorothiazide or metolazone
First Intervention (4 Days)
STARTED
4
4
First Intervention (4 Days)
COMPLETED
4
4
First Intervention (4 Days)
NOT COMPLETED
0
0
Washout (7 Days)
STARTED
4
4
Washout (7 Days)
COMPLETED
4
4
Washout (7 Days)
NOT COMPLETED
0
0
Second Intervention (4 Days)
STARTED
4
4
Second Intervention (4 Days)
COMPLETED
4
4
Second Intervention (4 Days)
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm 1
n=8 Participants
A Randomized, double-blind, crossover study designed to compare the efficacy of furosemide in combination with hydrochlorothiazide or metolazone in congestive heart failure patients. First Intervention with Furosemide and Hydrochlorothiazide (4 days), Washout (7 days), and Second Intervention with Furosemide + Metolazone(4 days).
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
3 participants
n=5 Participants
Race/Ethnicity, Customized
Other
5 participants
n=5 Participants

PRIMARY outcome

Timeframe: First Intervention (4 days), Washout (7 days), and Second Intervention (4 days)

Outcome measures

Outcome measures
Measure
Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone
n=4 Participants
A Randomized, double-blind, crossover study designed to compare the efficacy of furosemide in combination with hydrochlorothiazide or metolazone in congestive heart failure patients. First Intervention-Furosemide and Hydrochlorothiazide (4 days) Washout (7 days) Second Intervention-Furosemide + Metolazone (4 days) Combined results for both therapies are being reported since it cannot be determined which arm/group was assigned to Hydrochlorothiazide or metolazone
Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide
n=4 Participants
A Randomized, double-blind, crossover study designed to compare the efficacy of furosemide in combination with hydrochlorothiazide or metolazone in congestive heart failure patients. First Intervention-Furosemide and Metolazone (4 days) Washout (7 days) Second Intervention-Furosemide and Hydrochlorothiazide (4 days), Combined results for both therapies are being reported since it cannot be determined which arm/group was assigned to Hydrochlorothiazide or metolazone
Participants With Change in Urinary Output
First Intervention (4 days)
4 participants
4 participants
Participants With Change in Urinary Output
Washout (7 days)
4 participants
4 participants
Participants With Change in Urinary Output
Second Intervention (4 days)
4 participants
4 participants

Adverse Events

Arm 1-First Intervention-Furosemide + Hydrochlorothiazide

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Arm 1-Second Intervention-Furosemide + Metolazone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Arm 2-First Intervention-Furosemide + Metolazone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Arm 2-Second Intervention-Furosemide + Hydrochlorothiazide

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Joe Anderson

University of New Mexico Health Sciences

Phone: 505-272-3664

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place